Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9597
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCooper, Mark Een
dc.contributor.authorRumble, J Ren
dc.contributor.authorGin, Ten
dc.contributor.authorLim-Joon, Ten
dc.date.accessioned2015-05-15T22:45:15Z
dc.date.available2015-05-15T22:45:15Z
dc.date.issued1992-05-16en
dc.identifier.citationClinical and Experimental Pharmacology & Physiology. Supplement; 19(): 23-7en
dc.identifier.govdoc1395113en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/9597en
dc.description.abstract1. It has been suggested that hypertension may be an important determinant of the rate of progression of diabetic microangiopathy. 2. Renal microvascular disease as assessed by urinary albumin excretion and glomerular ultrastructure was evaluated in a model in which streptozotocin diabetes was induced in spontaneously hypertensive rats (SHR). 3. Diabetes was associated with increases in urinary albumin excretion, and hypertension resulted in a further increase in albuminuria. 4. Various antihypertensive regimens were administered to diabetic SHR, with the angiotensin-converting enzyme inhibitor perindopril and triple therapy (hydralazine, reserpine and hydrochlorothiazide) being more effective than the calcium antagonist (lacidipine) in retarding the increase in albuminuria in diabetic SHR. 5. Antihypertensive therapy appears to ameliorate the development of diabetic renal disease.en
dc.language.isoenen
dc.subject.otherAlbuminuria.etiologyen
dc.subject.otherAngiotensin-Converting Enzyme Inhibitors.therapeutic useen
dc.subject.otherAnimalsen
dc.subject.otherAntihypertensive Agents.therapeutic useen
dc.subject.otherCalcium Channel Blockers.therapeutic useen
dc.subject.otherDiabetes Mellitus, Experimental.complicationsen
dc.subject.otherDiabetic Angiopathies.etiology.prevention & controlen
dc.subject.otherDiabetic Nephropathies.etiologyen
dc.subject.otherDihydropyridines.therapeutic useen
dc.subject.otherHypertension, Renovascular.complications.drug therapyen
dc.subject.otherIndoles.therapeutic useen
dc.subject.otherKidney Glomerulus.ultrastructureen
dc.subject.otherMaleen
dc.subject.otherPerindoprilen
dc.subject.otherRatsen
dc.subject.otherRats, Inbred SHRen
dc.subject.otherRats, Inbred WKYen
dc.titleDiabetic renal microvascular disease: the role of hypertension and ACE inhibitors.en
dc.typeJournal Articleen
dc.identifier.journaltitleClinical and Experimental Pharmacology & Physiology. Supplementen
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.description.pages23-7en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/1395113en
dc.type.austinJournal Articleen
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

4
checked on Jan 29, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.